EMBC Overview

Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.

Wall Street analysts forecast EMBC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMBC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Embecta Corp revenue for the last quarter amounts to 221.80M USD, decreased -14.36

Embecta Corp. EPS for the last quarter amounts to -0.07 USD, decreased -117.50

Embecta Corp (EMBC) has 1850 emplpoyees as of June 21 2026.

Today EMBC has the market capitalization of 184.51M USD.